These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12604520)

  • 1. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Gunderson BW; Ibrahim KH; Hovde LB; Fromm TL; Reed MD; Rotschafer JC
    Antimicrob Agents Chemother; 2003 Mar; 47(3):905-9. PubMed ID: 12604520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa.
    D'Souza BB; Padmaraj SR; Rekha PD; Tellis RC; Prabhu S; Pothen P
    Microb Drug Resist; 2014 Dec; 20(6):550-4. PubMed ID: 25055029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
    den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.
    Chan EL; Zabransky RJ
    Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
    Dundar D; Otkun M
    Yonsei Med J; 2010 Jan; 51(1):111-6. PubMed ID: 20046523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.
    Bergen PJ; Forrest A; Bulitta JB; Tsuji BT; Sidjabat HE; Paterson DL; Li J; Nation RL
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5134-42. PubMed ID: 21876058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
    Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
    Zhanel GG; Mayer M; Laing N; Adam HJ
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2228-30. PubMed ID: 16723591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Oie S; Fukui Y; Yamamoto M; Masuda Y; Kamiya A
    BMC Infect Dis; 2009 Aug; 9():123. PubMed ID: 19664245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of two antimicrobial peptides, Nisin and P10 with conventional antibiotics against extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates.
    Jahangiri A; Neshani A; Mirhosseini SA; Ghazvini K; Zare H; Sedighian H
    Microb Pathog; 2021 Jan; 150():104700. PubMed ID: 33346078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.
    den Hollander JG; Mouton JW; Verbrugh HA
    Antimicrob Agents Chemother; 1998 Apr; 42(4):744-8. PubMed ID: 9559776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
    Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of colistin, imipenem and ceftazidime against drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in the south of Iran.
    Malekzadegan Y; Abdi A; Heidari H; Moradi M; Rastegar E; Sedigh Ebrahim-Saraie H
    BMC Res Notes; 2019 May; 12(1):301. PubMed ID: 31138309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.
    Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.